Residual mass: An indication for further therapy in patients with advanced seminoma following systemic chemotherapy Journal Article


Authors: Motzer, R.; Bosl, G.; Heelan, R.; Fair, W.; Whitmore, W.; Sogani, P.; Herr, H.; Morse, M.
Article Title: Residual mass: An indication for further therapy in patients with advanced seminoma following systemic chemotherapy
Abstract: Forty-one advanced seminoma patients with normal biochemical markers and a complete or partial radiographic response after cisplatin-based chemotherapy had a complete reevaluation of all known sites of disease. Twenty-three patients had a residual mass, and in 14 the mass was ≥ 3 cm. Nineteen patients with a residual mass, including 13 with a mass ≥ 3 cm in diameter, had surgical excision or biopsy. Four patients had viable seminoma and one patient had teratoma; all five of these patients had residual masses ≥ 3 cm. Four patients with a residual mass were observed without surgery. One patient with a residual mass ≥ 3 cm progressed with biopsy-proven seminoma. Therefore, six of 14 patients (42%) with a residual mass ≥ 3 cm had viable residual tumor. Eighteen patients had no residual mass after chemotherapy. Ten of these patients had surgery or biopsy; none had viable tumor, but two have relapsed. Advanced seminoma patients with a residual mass ≥ 3 cm after chemotherapy are at high risk for residual viable tumor. Additional therapy is indicated for these patients. For patients with normal imaging studies or a residual mass < 3 cm, close observation without surgery is generally possible.
Keywords: clinical article; cisplatin; advanced cancer; etoposide; testis cancer; seminoma; human; male
Journal Title: Journal of Clinical Oncology
Volume: 5
Issue: 7
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1987-07-01
Start Page: 1064
End Page: 1070
Language: English
DOI: 10.1200/jco.1987.5.7.1064
PUBMED: 3598610
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 5 February 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer
  2. Pramod C Sogani
    75 Sogani
  3. Harry W Herr
    594 Herr
  4. George Bosl
    430 Bosl
  5. Robert T Heelan
    140 Heelan
  6. William R Fair
    342 Fair
  7. Willet F. Whitmore Jr
    139 Whitmore
  8. Michael J. Morse
    40 Morse